A detailed history of Blue Owl Capital Holdings LP transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Blue Owl Capital Holdings LP holds 4,166,829 shares of LRMR stock, worth $25.7 Million. This represents 9.0% of its overall portfolio holdings.

Number of Shares
4,166,829
Previous 3,859,468 7.96%
Holding current value
$25.7 Million
Previous $28 Million 2.46%
% of portfolio
9.0%
Previous 11.62%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.3 - $10.68 $1.94 Million - $3.28 Million
307,361 Added 7.96%
4,166,829 $27.3 Million
Q2 2024

Aug 15, 2024

SELL
$6.33 - $9.89 $854,550 - $1.34 Million
-135,000 Reduced 3.38%
3,859,468 $28 Million
Q1 2024

May 15, 2024

BUY
$4.2 - $13.28 $2.44 Million - $7.7 Million
580,000 Added 16.99%
3,994,468 $30.3 Million
Q4 2023

Feb 14, 2024

BUY
$2.35 - $4.71 $8.02 Million - $16.1 Million
3,414,468 New
3,414,468 $15.5 Million

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $267M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Blue Owl Capital Holdings LP Portfolio

Follow Blue Owl Capital Holdings LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Owl Capital Holdings LP, based on Form 13F filings with the SEC.

News

Stay updated on Blue Owl Capital Holdings LP with notifications on news.